Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Abstract Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distrib...

Full description

Bibliographic Details
Main Authors: Lydian A. Huisman, Pieter J. Steinkamp, Jan-Luuk Hillebrands, Clark J. Zeebregts, Matthijs D. Linssen, Annelies Jorritsma-Smit, Riemer H. J. A. Slart, Gooitzen M. van Dam, Hendrikus H. Boersma
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-82568-8

Internet

https://doi.org/10.1038/s41598-021-82568-8

Similar Items